Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (TACEHCC)

Sun Yat-sen University

Status and phase

Completed

Phase 4

Conditions

Hepatocellular Carcinoma

Treatments

Procedure: transcatheter arterial chemoembolization

Study type

Interventional

Funder types

Other

Identifiers

NCT00646100

TACE1

Details and patient eligibility

About

Transcatheter arterial chemoembolization (TACE) had been proved to improve the survivals for middle stage hepatocellular carcinoma (HCC), but for advanced stage HCC its' efficacy had not been proved. The investigators hypothesize that TACE also improve the survivals for advanced stage HCC. Thus, the investigators carried out this prospective control study to find out if the survivals for patients after TACE better than only best support or not.

Enrollment

164 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL)
Tumor size >7 cm with a portal vein invasion, and the tumor was considered to be unresectable
No previous HCC directed treatment
Eastern Co-operative Group performance status 0-1
Liver function: Child's A

Exclusion criteria

Avascular tumor
Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
underlying serve cardiac or renal diseases
Known or suspected allergy to the investigational agent or any agent given in association with this trial
Diffuse-type HCC
For patients with main portal vein occlusion, no adequate collateral circulation around the occluded portal vein